| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| levothyroxine sodium | Tablet, uncoated | 100 microgram | Current | Unavailable | Manufacturing | 8/12/2025 |
| levothyroxine sodium | Tablet, uncoated | 50 microgram | Current | Unavailable | Manufacturing | 8/12/2025 |
| thiotepa | Injection, powder for | 15 mg | Current | Unavailable | Commercial Changes / Commercial viability | 8/12/2025 |
| thiotepa | Injection, powder for | 100 mg | Current | Unavailable | Commercial Changes / Commercial viability | 8/12/2025 |
| thiotepa | Injection, powder for | 400 mg | Current | Unavailable | Commercial Changes / Commercial viability | 8/12/2025 |
| simvastatin | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 8/12/2025 |
| trandolapril | Capsule | 2 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 5/12/2025 |
| topiramate | Tablet, film coated | 25 mg | Current | Unavailable | Manufacturing | 5/12/2025 |
| pioglitazone hydrochloride | Tablet | 49.9 mg | Resolved | Available | Manufacturing | 5/12/2025 |
| hydrochlorothiazide~valsartan | Tablet, film coated | 12.5 mg~160 mg | Anticipated | Available | Manufacturing | 5/12/2025 |
| phenobarbital | Tablet, uncoated | 30 mg | Current | Unavailable | Manufacturing | 5/12/2025 |
| quetiapine fumarate | Tablet, film coated | 115.12 mg | Resolved | Available | Commercial Changes / Commercial viability | 5/12/2025 |
| quetiapine fumarate | Tablet, film coated | 345.36 mg | Resolved | Available | Commercial Changes / Commercial viability | 5/12/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Unexpected increase in consumer demand | 5/12/2025 |
| citalopram hydrobromide | Tablet, film coated | 12.495 mg | Current | Limited Availability | Manufacturing | 5/12/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Unexpected increase in consumer demand | 5/12/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 5/12/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 5/12/2025 |
| moxonidine | Tablet, film coated | 200 microgram | Current | Limited Availability | Commercial Changes / Commercial viability | 5/12/2025 |
| mebeverine hydrochloride | Tablet, film coated | 135 mg | Resolved | Available | Manufacturing | 5/12/2025 |
| eplerenone | Tablet, film coated | 50 mg | Current | Limited Availability | Manufacturing | 5/12/2025 |
| eplerenone | Tablet, film coated | 25 mg | Current | Limited Availability | Manufacturing | 5/12/2025 |
| lacosamide | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 5/12/2025 |
| lacosamide | Tablet, film coated | 150 mg | Current | Unavailable | Manufacturing | 5/12/2025 |
| amlodipine besilate~olmesartan medoxomil~hydrochlorothiazide | Tablet, film coated | 13.9 mg~40 mg~12.5 mg | Resolved | Available | Manufacturing | 5/12/2025 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Current | Limited Availability | Manufacturing | 5/12/2025 |
| atracurium besilate | Injection, solution | 10 mg/mL | Current | Limited Availability | Manufacturing | 5/12/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | 1 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 5/12/2025 |
| flunitrazepam | Tablet, film coated | 1 mg | Current | Limited Availability | Manufacturing | 5/12/2025 |
| tobramycin | Injection, solution | 80 mg | Current | Emergency Supply Only | Manufacturing | 4/12/2025 |
| phenytoin sodium | Injection, solution | 250 mg | Current | Unavailable | Manufacturing | 4/12/2025 |
| phenytoin sodium | Injection, solution | 100 mg | Current | Unavailable | Manufacturing | 4/12/2025 |
| methylprednisolone sodium succinate | Injection, powder for | 663.13 mg | Anticipated | Available | Manufacturing | 4/12/2025 |
| dantrolene sodium hemiheptahydrate | Injection, powder for | 20 mg | Anticipated | Available | Manufacturing | 4/12/2025 |
| nortriptyline | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 4/12/2025 |
| midazolam | Injection, solution | 15 mg | Current | Limited Availability | Manufacturing | 4/12/2025 |
| midazolam | Injection, solution | 50 mg | Resolved | Available | Manufacturing | 4/12/2025 |
| trimethoprim~sulfamethoxazole | Injection, concentrated | 16 mg/mL~80 mg/mL | Current | Unavailable | Manufacturing | 4/12/2025 |
| bisoprolol fumarate | Tablet | 5 mg | Resolved | Available | Manufacturing | 4/12/2025 |
| rocuronium bromide | Injection, solution | 50 mg | Anticipated | Available | Manufacturing | 4/12/2025 |
| sildenafil citrate | Tablet, film coated | 140.45 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 4/12/2025 |
| omeprazole | Capsule, enteric | 20 mg | Current | Limited Availability | Manufacturing | 4/12/2025 |
| indapamide hemihydrate~perindopril erbumine | Tablet | 1.25 mg~4 mg | Current | Unavailable | Manufacturing | 4/12/2025 |
| simvastatin~ezetimibe | Tablet | 10 mg~10 mg | Current | Unavailable | Manufacturing | 4/12/2025 |
| simvastatin~ezetimibe | Tablet | 80 mg~10 mg | Anticipated | Available | Manufacturing | 4/12/2025 |
| ezetimibe~simvastatin | Tablet | 10 mg~20 mg | Current | Unavailable | Manufacturing | 4/12/2025 |
| ezetimibe~simvastatin | Tablet | 10 mg~40 mg | Anticipated | Available | Manufacturing | 4/12/2025 |
| acarbose | Tablet | 50 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 4/12/2025 |
| acarbose | Tablet | 100 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 4/12/2025 |
| paclitaxel | Injection, powder for | 100 mg | Resolved | Available | Manufacturing | 4/12/2025 |
| paroxetine hydrochloride | Tablet, film coated | 22.22 mg | Current | Limited Availability | Manufacturing | 4/12/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.751 mg | Current | Limited Availability | Manufacturing | 4/12/2025 |
| lamotrigine | Tablet, chewable | 100 mg | Current | Unavailable | Manufacturing | 4/12/2025 |
| daptomycin | Injection, powder for | 500 mg | Current | Unavailable | Manufacturing | 4/12/2025 |
| daptomycin | Inhalation, powder for | 350 mg | Current | Unavailable | Manufacturing | 4/12/2025 |
| isotretinoin | Capsule, soft | 10 mg | Current | Limited Availability | Manufacturing | 4/12/2025 |
| alprostadil | Injection, solution | 500 microgram/mL | Anticipated | Available | Manufacturing | 4/12/2025 |
| rifampicin | Capsule, hard | 150 mg | Resolved | Available | Manufacturing | 4/12/2025 |
| rifampicin | Capsule, hard | 300 mg | Resolved | Available | Manufacturing | 4/12/2025 |
| Insulin lispro | Injection, solution | 100 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 4/12/2025 |
| Alteplase | Diluent, not applicable | 10 mg | Resolved | Available | Unexpected increase in consumer demand | 4/12/2025 |
| heparin sodium | Injection, solution | 10 IU/mL | Current | Unavailable | Manufacturing | 4/12/2025 |
| nizatidine | Capsule | 300 mg | Current | Limited Availability | Manufacturing | 4/12/2025 |
| sertraline hydrochloride | Tablet, film coated | 56 mg | Anticipated | Available | Manufacturing | 4/12/2025 |
| sertraline hydrochloride | Tablet, film coated | 112 mg | Anticipated | Available | Manufacturing | 4/12/2025 |
| dinoprostone | Gel | .3333 mg/g | Current | Emergency Supply Only | Manufacturing | 4/12/2025 |
| dinoprostone | Gel | .6667 mg/g | Current | Emergency Supply Only | Manufacturing | 4/12/2025 |
| venlafaxine | Capsule, modified release | 150 mg | Current | Unavailable | Manufacturing | 3/12/2025 |
| insulin | Injection, suspension | 100 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 3/12/2025 |
| insulin | Injection, solution | 100 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 3/12/2025 |
| glipizide | Tablet, uncoated | 5 mg | Anticipated | Available | Manufacturing | 3/12/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 3/12/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 3/12/2025 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Resolved | Available | Unexpected increase in consumer demand | 3/12/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 3/12/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 3/12/2025 |
| lamotrigine | Tablet, uncoated | 100 mg | Current | Unavailable | Manufacturing | 3/12/2025 |
| icatibant acetate | Injection, solution | 31.38 mg | Resolved | Available | Manufacturing | 3/12/2025 |
| insulin | Injection, suspension | 100 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 3/12/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 3/12/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Current | Unavailable | Manufacturing | 3/12/2025 |
| mianserin hydrochloride | Tablet, film coated | 20 mg | Resolved | Available | Manufacturing | 3/12/2025 |
| labetalol hydrochloride | Tablet, film coated | 100 mg | Current | Unavailable | Manufacturing | 3/12/2025 |
| spironolactone | Tablet, film coated | 25 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/12/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 2/12/2025 |
| sodium nitroprusside | Injection, solution | 50 mg | Resolved | Available | Manufacturing | 2/12/2025 |
| lansoprazole | Tablet, orally disintegrating | 30 mg | Current | Limited Availability | Manufacturing | 2/12/2025 |
| nicorandil | Tablet | 20 mg | Resolved | Available | Manufacturing | 2/12/2025 |
| nicorandil | Tablet | 10 mg | Resolved | Available | Manufacturing | 2/12/2025 |
| hydrocortisone | Tablet, uncoated | 4 mg | Current | Unavailable | Manufacturing | 2/12/2025 |
| daptomycin | Injection, powder for | 500 mg | Resolved | Available | Manufacturing | 2/12/2025 |
| methyldopa sesquihydrate | Tablet, film coated | 283 mg | Resolved | Available | Manufacturing | 2/12/2025 |
| dapsone | Tablet, uncoated | 25 mg | Anticipated | Available | Manufacturing | 1/12/2025 |
| dapsone | Tablet, uncoated | 100 mg | Anticipated | Available | Manufacturing | 1/12/2025 |
| indometacin | Suppository, moulded | 100 mg | Resolved | Available | Manufacturing | 1/12/2025 |
| metoprolol tartrate | Injection, solution | 1 mg/mL | Anticipated | Available | Manufacturing | 1/12/2025 |
| drospirenone~ethinylestradiol | Tablet | 3 mg~30 microgram | Current | Limited Availability | Manufacturing | 1/12/2025 |
| finasteride | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 1/12/2025 |
| paclitaxel | Injection, concentrated | 300 mg | Current | Unavailable | Manufacturing | 1/12/2025 |
| codeine phosphate hemihydrate | Oral Liquid | 5 mg/mL | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 1/12/2025 |
| peramivir | Injection, concentrated | 10 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 1/12/2025 |
| moxonidine | Tablet, film coated | 200 microgram | Anticipated | Available | Commercial Changes / Commercial viability | 1/12/2025 |
| lacosamide | Tablet, film coated | 100 mg | Current | Limited Availability | Manufacturing | 1/12/2025 |
| lacosamide | Tablet, film coated | 50 mg | Current | Limited Availability | Manufacturing | 1/12/2025 |
| aprepitant | Capsule, hard | 165 mg | Anticipated | Available | Manufacturing | 1/12/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Unavailable | Manufacturing | 1/12/2025 |
| oseltamivir phosphate | Capsule, hard | 98.524 mg | Resolved | Available | Manufacturing | 1/12/2025 |
| finasteride | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 1/12/2025 |
| levothyroxine sodium | Tablet, uncoated | .05 mg | Current | Limited Availability | Manufacturing | 1/12/2025 |
| tetrabenazine | Tablet, uncoated | 25 mg | Current | Unavailable | Manufacturing | 1/12/2025 |
| lidocaine hydrochloride | Injection, solution | 10 mg/mL | Current | Limited Availability | Manufacturing | 1/12/2025 |
| ropivacaine hydrochloride | Injection, solution | 10 mg/mL | Current | Limited Availability | Manufacturing | 1/12/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Limited Availability | Manufacturing | 1/12/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Unavailable | Manufacturing | 1/12/2025 |
| cabergoline | Tablet, uncoated | 1 mg | Anticipated | Available | Manufacturing | 1/12/2025 |
| dalteparin sodium | Injection, solution | 18000 anti-Xa IU | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 1/12/2025 |
| dosulepin hydrochloride | Tablet, film coated | 75 mg | Resolved | Available | Manufacturing | 1/12/2025 |
| reboxetine mesilate | Tablet, uncoated | 5.224 mg | Anticipated | Available | Commercial Changes / Commercial viability | 1/12/2025 |
2025年12月8日